Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan.

Mol Clin Oncol · 2015 · PMC4665969 · PMID 26807231

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

The interim analysis of overall survival (OS) exhibited a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.